Septal reduction therapy remains a cornerstone in the management of drug-refractory obstructive hypertrophic cardiomyopathy (HOCM), with surgical myectomy and alcohol septal ablation (ASA) as established modalities. However, both approaches are limited by procedural morbidity, particularly injury to the cardiac conduction system. This editorial examines a preclinical investigation by Xu et al., which evaluates a novel retractable needle-tipped radiofrequency (RF) ablation catheter designed to deliver intramyocardial energy with the aim of preserving the subendocardium. Using a healthy canine model, this technique generated significantly deeper and broader lesions compared to conventional surface RF ablation, with associated reductions in septal motion and no observed compromise in conduction parameters or global cardiac function. While constrained by the use of healthy dogs rather than a true HOCM model and a small sample size, the findings point to the potential of this approach as a minimally invasive, conduction-sparing alternative for septal reduction, while leaving many remaining questions. This commentary contextualizes the study within the evolving field of structural electrophysiology and highlights the imperative for further translational and clinical evaluation of novel ablation technologies.

This paper explores the innovative approach of cardiac calcium electroporation as a potential advancement in catheter ablation techniques, building upon the historical context of thermal ablation methods. While traditional radiofrequency and cryothermal ablation have significantly improved efficacy and safety, the risk of collateral damage persists. Pulsed-field ablation (PFA) has emerged as a promising non-thermal alternative designed to target cardiac myocytes while sparing adjacent tissues. However, concerns about unintended consequences remain. In this study by Toya et al., the efficacy of low-power PFA augmented with calcium chloride infusion resulted in enhanced lesion formation, with increased surface area, volume, and histological damage, suggesting a potential for improved targeted ablation. Despite these findings, the study acknowledges limitations, including a small sample size and the need for further investigation into calcium’s effects on lesion durability and safety. This exploration represents a nascent step toward redefining cardiac ablation practices, highlighting the possibility of enhanced therapeutic and safety outcomes through innovative strategies. As PFA continues to evolve, incorporating calcium electroporation may further separate the overlapping risks of effective tissue ablation from collateral damage, signaling a transformative shift in cardiac electrophysiology.

While advances in catheter design and power delivery combined with increased awareness among operators have given more tools to avoid collateral damage, the results obtained in the accompanied manuscript are a warning that 50W and 90W 4sec LA lesions guided by 400 AI and 5 LSI using TactiCath, STSF, and QDOT MICRO do not provide immunity from significant extracardiac injury.